Introduction
Fetuin-A is a human secretory protein of liver, possessing multiple physiological and pathological functions as regulation of insulin resistance, inhibition of soft and vascular tissue calci cation, bone metabolism regulation, regulation of proteolytic activity, keratinocyte migration, and tumorigenesis cell proliferative signaling [1] . It is a highly expressed glycoprotein in various fetal tissues whereas it is mainly expressed in the liver in adults [2] .
The structure of fetuin-A includes two disul de-bonded peptides [5] , forming three domains -two cystatin domains D1 and D2, and C-terminal speci c region [6] . Posttranslationally, after proteolytic processing it undergoes: glycosylation [7] , phosphorylation [8, 9] and sulfation [10] . As a glycoprotein, it contains three N-linked branched glycans [11] and four sites of O-linked glycosylation, forming approximately 23.6% of carbohydrate [12] . Posttranslational modi cations may attenuate its biological stability and activity [13] .
Phosphorylation of serine residues (Ser 120 and Ser 312 ) is essential for fetuin-A interaction with the insulin receptor and inhibitory activity [14] . Ser 312 seems to be a site of regulatory covalent modi cations, whereas Ser 120 was shown to be constitutively phosphorylated. Approximately 20% of fetuin-A in circulation is phosphorylated [10] . In the studies of Brown et al. (1992) and Diegielewska et al. (1996) , the complementary deoxyribonucleic acid (cDNAs) encoding human, sheep, cow, rat, mouse, and pig fetuin-A were compared, and high sequence identity was shown [15, 16] .
Fetuin-A and insulin resistance
Fetuin-A is a physiological insulin receptor inhibitor. It induces insulin resistance and alters metabolism in insulin-sensitive tissues by inhibition of the autophosphorylation of tyrosine kinase. The most affected tissues are the liver, adipose tissue, muscles, hypothalamus where it disturbs cell signaling pathways and homeostasis [17] .
The role of fetuin-A in the mechanism of insulin resistance was demonstrated in animal models and humans. Acute injection of human recombinant fetuin-A in rats has shown to suppress the activity of the tyrosine kinase and insulin receptor substrate protein (IRS-1) in muscles and the liver. The mechanism of action of fetuin-A includes inhibition of the autophosphorylation of the enzyme (tyrosine kinase) and extracellular signal-regulated kinase (ERK) 1/2 mitogenic signaling arm [14, 15] . Studies in fetuin-A knockout mice demonstrated increased phosphorylation of insulin receptor and improved insulin sensitivity [18] . Fetuin-A knockout mice on a high-fat diet have been found to have lower serum lipids (free fatty acid and triacylglycerol) and protected from overweight and obesity [19] .
Studies in humans demonstrated that fetuin-A level was positively associated with fasting. Low levels of fetuin-A on fasting stimulated insulin release, and negatively correlated with insulin sensitivity as measured by the euglycemic hyperinsulinemic clamp [20] . High fetuin-A plasma levels predict reduced insulin sensitivity. Dysregulated insulin sensitivity leads to the development of metabolic syndrome [21] , an increased risk for T2DM [22] , dyslipidaemias and cardio-vascular diseases. The detailed mechanism of blocking the metabolic arm of insulin action by fetuin-A/AHSG was investigated by Goustin et al. (2013) [23] .
In the study on mouse myoblasts, it was demonstrated that fetuin-A binding to the insulin receptor blocks glucose transporter type 4 (GLUT4) translocation in response to insulin action through the inhibition of autophosphorylation of the 95 kD -subunit of insulin holoreceptor in a cell-free system [24] . Fetuin-A antagonizes the metabolic functions initiated by insulin receptor activation without the interference of insulin binding to the receptor. The experimental data support the suggestion of a direct interaction of fetuin-A with the insulin receptor -subunit ectodomain, in a way that does not interfere the high-af nity insulin binding of -subunit of the receptor.
The developed three-dimensional model of rat AHSG indicated the putative epitope, possibly interacting with the beta-subunit ectodomain of the insulin receptor (INSR) [24] . These experiments demonstrated that fetuin-A might be an allosteric modulator of the INSR.
Fetuin-A role in increased risk of T2DM
T2DM is a major global public health threat. In 2012 there were 1.5 million deaths worldwide directly caused by diabetes (the eighth leading cause of death) as reported by WHO (2016) [25] . T2DM is mostly preventable, and evaluation of proper risk factors is essential for its prevention. The EPIC-Potsdam Study and prospective cohort study A found a positive association of fetuin-A levels with risk of T2DM [26] . Thus it was linked to the development of insulin resistance as an independent factor measured by the index of homeostasis model (HOMA-IR).
Fetuin-A interaction with INSR and IRS-1 is suggested as a novel mechanism involved in the pathophysiology of T2DM [27] .
The levels of circulating fetuin-A were demonstrated to correlate with diminished glucose tolerance, insulin resistance and T2DM in humans. The study of Norbert et al. (2008) showed that plasma fetuin-A levels are predictive for the incidence of T2DM independently of other established risk factors, particularly in individuals with elevated plasma glucose [28] . Furthermore, some studies provided data that fetuin-A is strongly associated with fat accumulation in the liver, non-alcohol induced fatty liver disease, and metabolic syndrome [29] . The investigated fetuin-A gene polymorphisms were proved to associate with T2DM, and impaired insulin sensitivity in adipocytes [30] .
Fetuin-A levels reveal a divergent correlation with pro-in ammatory markers in patients with T2DM. The investigation of in ammatory mediators or activation markers in T2DM patients by Sindhu et al. (2016) demonstrated a reciprocal correlation between plasma levels of fetuin-A and interleukin (IL)-1 , IL-7, IL-15, tumor necrosis factor alpha (TNF-), chemokine ligand (CCL)-2, CCL4, soluble CD40L (sCD40L), growth related oncogene (GRO), elongation factor F (EFF) 2, and vascular endothelial growth factor (VEGF) [31] . The study provided evidence that fetuin-A levels are reciprocally associated with the pro-in ammatory cytokines and biomarkers that possess a predictive value of fetuin-A as a negative acute phase protein in patients with T2DM.
Early stage pro-in ammatory cytokines interferon gamma (IFN-), IL-1 and TNFwere demonstrated to be rather inhibitory regulators of liver synthesis of fetuin-A [32] . The negative correlation between pro-in ammatory cytokines and fetuin-A levels in T2DM patients may predict lower fetuin-A levels in the presence of increased pro-in ammatory markers.
Altogether, these investigations testify that plasma fetuin-A levels correlate with impaired glucose tolerance and insulin resistance, and inversely correlate with in ammatory and activation biomarkers in patients with T2DM. Circulatory fetuin-A levels may have plausible predictive importance as a biomarker of risk for diabetes and negative acute phase protein [33] . A systematic review of 11497 individuals, 2176 cases of T2DM and meta-analysis indicated that higher circulating fetuin-A levels were related to increased risk of T2DM. The association was gender-related and particularly evident in women. A signi cant relationship between fetuin-A levels with T2DM risk was demonstrated in many systematic reviews [34] .
The role of fetuin-A in metabolic syndrome and its components
A close relationship of fetuin-A with metabolic syndrome has been demonstrated in crosssectional studies [35] . The suggestion that fetuin-A level in humans is related to the development of the metabolic syndrome phenotype is supported by a few studies, indicating a correlation of fetuin-A with many components of metabolic syndrome such as high blood pressure, waist circumference, and cholesterol levels [36] . In patients with coronary artery disease (non-diabetic) a higher level of fetuin-A correlated with metabolic syndrome and atherogenic lipid pro le according to a study on middle-aged and elderly Chinese subjects, and the Heart and Soul Study [21, 37, 38] .
Adiponectin is also known to be involved in the regulation of insulin sensitivity. It is the insulin-sensitizing adipocytokine -a valuable element of the body sensitivity and risk of CVDs. Adiponectin production may be suppressed by fetuin-A [39] .
High levels of fetuin-A in the circulation appear to promote insulin resistance and, particularly in patients with diabetic nephropathy; such levels could be directly related to vascular calci cation.
The cross-sectional studies provide the evidence of an essential role of low level of fetuin-A as a risk factor in dialysis patients. An association with cardiovascular and all-cause mortality was con rmed [40] .
The role of fetuin-A in regulating insulin sensitivity, postprandial glucose clearance, and fat accumulation provides a new understanding of these processes. It is assumed that in the future it could be used for the novel approach to the therapy of T2DM, metabolic syndrome and insulin resistance [41] .
In line with the latest data from the studies, it could be assumed that synthesis of fetuin-A can be diversely controlled in various disease conditions. This hepatokine could eventually serve as both positive and negative acute phase protein in various morbid states [32] .
Fetuin in obesity
Recently, it was demonstrated that subcutaneous and visceral adipose tissue secrete fetuin-A.
The relationship between the circulating levels of fetuin-A and fat mass was investigated in animal studies in various conditions such as diet-induced obesity, weight loss induced by exercise, and anorexia [42] . The expression and secretion pattern of fetuin-A by adipose tissue from visceral and subcutaneous stores at various physiological and nutritional conditions indicate the relation between fat mass, body weight, and secreted fetuin-A. Adipose tissue, apart from adipocytes, contains macrophages, endothelial cells, and broblasts (stromal fraction) contributing to the protein/peptide secretion pattern. Furthermore, the secretomes in white adipose tissue have been identi ed and analyzed recently [43, 44] .
The secretion of fetuin-A by visceral adipose tissue from anorectic animals is reduced. However, it is over-secreted by visceral adipose tissue in obesity [45] . The secretion of active phosphorylated at Ser 321 residue fetuin-A by visceral adipose tissue is independent of body mass index (BMI), while the fraction of activefetuin-A secreted by subcutaneous adipose tissue augments signi cantly in situations of obesity [44] . Altogether, visceral adipose tissue secretes more fetuin-A than subcutaneous adipose tissue. It worth noting that secretion of fetuin-A is related to physiological and nutritional changes. Weight loss has also been proved to reduce circulating fetuin-A levels in humans [46] .
Additionally, there is data proving that fetuin-A could in uence adipose tissue and stimulate in ammatory cytokine production by macrophages and adipocytes and thus induce total insulin resistance.
More recently, the studies on the effects of fetuin-A on toll-like receptor 4 (TLR-4) have proved that fetuin-A acts as an endogenous lipid induced ligand of TLR-4 of adipocyte in ammation and insulin resistance [46] .
Thus it might be suggested that in ammation in adipose tissue induced by free fatty acids could be mediated by fetuin-A and is not a direct effect [46] . The data on the increased secretion of fetuin-A by visceral adipose tissue, and particularly the augmented proportion of the phosphorylated (active) form of fetuin-A secreted by subcutaneous adipose tissue in obese animals suggest the critical role of fetuin in deleterious obesity consequences and comorbidities aggravated by the capacity of adipose-derived fetuin-A to inhibit the insulin pathway.
Fetuin role in CVD
CVDs are one of the major causes of death in the world amounting to almost 30% of all deaths. The number of studies that indicate an association between fetuin-A and CVDs is increasing. However, a divergent relationship was reported.
Some studies demonstrated that the patients with high fetuin-A concentrations had a higher (to 4-fold increased) risk of myocardial infarction and ischaemic stroke, as compared to subjects with low fetuin-A levels [47] . The risk was gender-related, and was higher in women than in men. In a study carried out by Rancho-Bernardo, raised fetuin-A levels correlated with lower risk of CVD death in patients without T2DM [48] , though in the T2DM patients there was a direct association of fetuin-A levels with CVDs [38] . A positive correlation of fetuin-A with arterial stiffness and increased intima-media thickness was detected in patients with normal renal function and in healthy subjects [49] .
Furthermore, fetuin-A plays a role in the development of subclinical in ammation, by promoting cytokine expression in human monocyte and thereby might have an effect on CVD risk [37, 50] .
Nonetheless, some clinical studies have reported opposite trends. Low fetuin-A levels were associated with the presence of peripheral arterial disease, atherosclerotic plaque calci cation, and increased arterial stiffness. In patients with stable angina and acute myocardial infarction, fetuin-A concentrations were lower [51, 52] . Several systematic reviews and metaanalyses evaluated the relationship between fetuin-A levels and the risk of CVDs. They provided contradictory results: the association with CVD risk in various prospective studies was found as a negative correlation (decreased serum fetuin-A level correlated with the development of CVDs) [53] , as re ecting the progression of CVDs [54] , or as inconsistent [55] .
In the paper of Roos et al. (2010) , a hypothesis of two-phase association of fetuin-A with vascular disease depending on the stage of atherosclerosis was suggested [56] . Higher fetuin-A circulation level in healthy diabetic and non-diabetic subjects without vascular pathology, correlated with CVD risks. However, a contradictory relationship was demonstrated in patients with established vascular disease [53] . It was assumed that in early CVD stages fetuin-A aggravates disease development due to induced insulin resistance and dyslipidemia. On the other hand, in patients with an already established CVDs high fetuin-A level was found to improve the clinical presentation, possibly due to the prevention of vascular Ca 2+ deposition by fetuin-A [32] .
Fetuin A in stroke patients
Of the estimated 17.3 million deaths from CVD in 2008, representing 30% of all global deaths, 13.8% were due to stroke. The primary cause of stroke includes hypertension, atherosclerosis leading to coronary artery disease, dyslipidemia, heart disease, and subclinical in ammation. The risk of stroke increases with age, and in subjects over 55, it doubles twice per decade. Patients with diabetes are at a higher risk of stroke than those without diabetes.
The in ammatory responses in cerebral ischemia are forced by speci c mediators secreted by neurons and microglia, as well as by in ltration of peripheral immune cells such as macrophages.
The correlation of elevated mediators of in ammation and ischemic stroke was demonstrated in several studies. Sezer et al. (2014) investigated the levels of fetuin-A, Pentraxin-3, and serum amyloid A in a group of patients with ischemic stroke. Their results proved a signi cant correlation between the in ammatory factors and disease severity and progression [57] . The positive correlation between high plasma fetuin-A concentrations and a signi cantly higher risk of ischemic stroke and myocardial infarction was found in the patients from the EPIC-Potsdam Study with ischemic stroke and myocardial infarction [49, 58] . A study of a group of 200 patients with stroke proved signi cantly higher fetuin-A levels in the group of patients with carotid plaque formation. Increased plasma in ammatory biomarker levels were accompanied by a high risk of carotid plaque formation and instability [59] . However, in a study of a female group with ischemic stroke, no signi cant relationship of the concentration of fetuin-A and risk of embolic or thrombotic stroke was found [60] .
An investigation of ischemic brain tissue in an animal model of focal cerebral ischemia demonstrated that the concentrations of fetuin-A changed in a time-dependent manner. The concentration of fetuin-A started to elevate around 2 and 6 h, reaching the highest values between 24 to 48 h and restored to baseline 72 h after middle cerebral artery occlusion [61] . As in ammation plays an important role in acute ischemic stroke, the investigation of the relationship between acute ischemic stroke and serum fetuin-A level could produce new insight on the disease development and progression.
Polycystic ovary syndrome (PCOS)
PCOS is a heterogeneous endocrine disorder. Its prevalence depends on the criteria applied from 6% to 10% according to the U.S. National Institutes of Health (NIH) criteria and lipidinduced 15% according to Rotterdam criteria [62, 63] . The clinical expression varies including oligo-or anovulation, hyperandrogenemia, and polycystic ovaries and commonly manifests in early reproductive years.
Women with PCOS are also more predisposed to insulin resistance and metabolic syndrome. Studies on the impact of fetuin-A in metabolic syndrome and insulin resistance inspired interest in its role in the patient with PCOS [64] .
It was shown that roughly 60-80% of women with PCOS are with insulin resistance, reaching a higher percentage when obese [65] . Some investigations assess the contribution of fetuin-A to triggering the processes, which leads to the development of PCOS and its important symptoms: insulin resistance and androgen excess [63, 64] .
A positive correlation of fetuin-A with insulin, a homeostatic model assessment of insulin resistance (HOMA-IR) and free androgen index (FAI) in PCOS patients was demonstrated in some studies [66] . Multiple regression analysis Komsa-Penkova R, et al. Fetuin-A-Alpha2-Heremans-Schmid Glycoprotein... revealed that free androgen index was strongly related to the serum fetuin-A level. Serum fetuin-A level was related to insulin resistance and ovarian hyperandrogenism in women with PCOS [67] .
Fetuin-A could be assumed as an important factor linking insulin resistance with obesity. Reduced insulin sensitivity and the resulting hyperinsulinemia were much more expressed than it was foreseen, as far as BMI was concerned in PCOS patients. It proves signi cant disturbances in metabolism in both obese and non-obese PCOS patients. In general, obesity in PCOS patients is associated with more expressed insulin resistance, hyperandrogenemia, and fertility problems.
In certain studies, higher serum concentrations of fetuin-A were found in obese women without PCOS, as compared to lean women. These concentrations decreased after major weight loss.
PCOS women with reproductive problems searching arti cial insemination with intracytoplasmic sperm injection (ICSI) showed no signi cant difference in serum fetuin-A levels, as compared to ICSI-treated non-PCOS ones [68] . However, fetuin-A level in follicular uid of non-PCOS women was signi cantly higher than that in the follicular uid of women with PCOS. Furthermore, there was no signi cant difference in serum or follicular uid of fetuin-A levels between PCOS women who succeeded in becoming pregnant and those who did not.
Since fetuin-A is a natural inhibitor of INSR activity, the association of fetuin-A with insulin resistance during pregnancy was investigated in several studies with contradictory results. In a case-control study by Farhan et al (2012) , acute glucose intake on performing glucose tolerance test and its in uence on serum fetuin-A level was investigated in women with gestational diabetes mellitus (GDM) (n=10) in the early third trimester and healthy controls (n=10) [69] . A correlation between fetuin-A and body mass index was demonstrated. However, no signi cant association with neither insulin sensitivity nor with insulin and C-peptide levels was found. There was no correlation with fetuin-A in later pregnancy or after pregnancy. In the study of Kalabay et al (2002) , including thirty pregnant patients with GDM; one hundred four healthy pregnant women and the same number of non-pregnant controls, the maternal serum levels of fetuin-A were assessed [70] . A correlation between serum fetuin levels and maternal parameters such as fasting C-peptide and C-peptide/glucose ratio was established, indirectly indicating the risk of insulin resistance. The results regarding a relationship with serum fetuin-A levels are rather contradictory.
The mean serum fetuin-A level was found to be considerably higher as compared to healthy controls in the investigation of Abali et al. (2013) [71] . The study by Gulhan et al. (2012) , on the other hand, revealed no difference between healthy controls and the patients with PCOS with regard to the level of fetuin-A [72] . Most likely, these controversial results might be attributed to the difference in insulin resistance and euglycemic control. Further studies are needed to assess the role of fetuin-A in PCOS patients and related fertility problems.
Conclusions
The role of fetuin-A in insulin resistance and related morbidities was investigated in numerous studies. The immediate impact on the physiological regulation of the activity of INSR, through attenuation of its action and the response to hyperglycaemia, dyslipidemia, Ca 2+ level and in ammatory condition was discussed. The role of fetuin-A as a potential disease marker, particularly concerning insulin resistance, T2DM, metabolic syndrome, CVDs, ischemic stroke, reproductive problems in PCOS or pregnancy complications (GDM, preeclampsia) was considered, as well as eventual drug management of these conditions.
